Company news

Ardelyx, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023

October 3, 2023

Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility

September 27, 2023

Tenapanor for Hyperphosphatemia Approved in Japan

September 24, 2023

Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023

September 10, 2023

Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 7, 2023

Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance

August 1, 2023

Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023

July 25, 2023

Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference

July 19, 2023

Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China

July 12, 2023

Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase

June 4, 2023

Ardelyx to Present at the Jefferies 2023 Healthcare Conference

May 30, 2023

Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)

May 16, 2023

Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

May 8, 2023

Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update

May 2, 2023

Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference

April 30, 2023

Ardelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023

April 25, 2023

Ardelyx Resubmits New Drug Application to U.S. Food and Drug Administration for XPHOZAH® (tenapanor)

April 17, 2023

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2023 Spring Clinical Meetings

April 11, 2023

Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

March 1, 2023

Ardelyx Publishes First Environmental, Social and Governance (ESG) Report

February 27, 2023

Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference

February 26, 2023

Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023

February 22, 2023

FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)

December 28, 2022

Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

December 15, 2022

Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference

November 21, 2022

Ardelyx Stock Trading Halted Today; FDA Advisory Committee to Discuss XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

November 15, 2022

Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

November 15, 2022

Ardelyx Reports Third Quarter 2022 Financial Results and Recent Business Highlights

November 2, 2022

Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on...

November 2, 2022

Ardelyx Collaboration Partner, Kyowa Kirin, Announces Submission of New Drug Application for Tenapanor for Hyperphosphatemia in Japan

October 30, 2022

Ardelyx to Report Third Quarter 2022 Financial Results on November 3, 2022

October 26, 2022

Ardelyx to Present Poster Presentations on IBSRELA® (tenapanor) for Adult Patients with IBS-C at the American College of Gastroenterology 2022 Annual Scientific Meeting

October 23, 2022

Ardelyx Announces Poster Presentations on XPHOZAH® (tenapanor) at ASN's Kidney Week 2022

October 19, 2022

Ardelyx Reports Second Quarter 2022 Financial Results and Recent Business Highlights

August 3, 2022

Ardelyx to Present at the 2022 Wedbush PacGrow Healthcare Conference

August 1, 2022

Ardelyx to Report Second Quarter 2022 Financial Results on August 4, 2022

July 27, 2022

Ardelyx Announces $20 Million Financing Agreement with HealthCare Royalty Partners

June 29, 2022

Ardelyx Announces FDA Advisory Committee Meeting to Review XPHOZAH® NDA Tentatively Scheduled for November 16, 2022

June 20, 2022

Ardelyx to Present at the Jefferies 2022 Healthcare Conference

June 2, 2022

Ardelyx Presents Data at DDW 2022 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults

May 23, 2022

Ardelyx Announces Additional Data Supporting the Efficacy and Safety of First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at DDW 2022

May 16, 2022

Ardelyx Reports First Quarter 2022 Financial Results and Recent Business Highlights

May 4, 2022

Ardelyx to Report First Quarter 2022 Financial Results on May 5, 2022

April 27, 2022

Ardelyx Announces FDA Plan to Convene Advisory Committee for XPHOZAH® (tenapanor)

April 24, 2022

Ardelyx and Kyowa Kirin Amend License Agreement for Tenapanor

April 10, 2022

Ardelyx Presents Positive Data Further Supporting Efficacy and Safety of XPHOZAH® (tenapanor) at National Kidney Foundation 2022 Spring Clinical Meetings

April 6, 2022

Ardelyx Announces US Launch of IBSRELA®, a New First-in-Class Treatment for IBS-C in Adults

April 3, 2022

Ardelyx to Participate at the Cowen 42nd Annual Health Care Conference

March 1, 2022

Ardelyx Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

February 27, 2022

Ardelyx Announces $27.5 Million Debt Financing Agreement with SLR Capital Partners

February 23, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 18 decks. Every deck is listed under its year.